PT1169062E - Óxidos de ferro coloidais termoestáveis revestidos - Google Patents

Óxidos de ferro coloidais termoestáveis revestidos Download PDF

Info

Publication number
PT1169062E
PT1169062E PT00914867T PT00914867T PT1169062E PT 1169062 E PT1169062 E PT 1169062E PT 00914867 T PT00914867 T PT 00914867T PT 00914867 T PT00914867 T PT 00914867T PT 1169062 E PT1169062 E PT 1169062E
Authority
PT
Portugal
Prior art keywords
iron oxides
heat stable
compositions
methods
colloidal iron
Prior art date
Application number
PT00914867T
Other languages
English (en)
Portuguese (pt)
Inventor
Ernest V Groman
Kenneth G Paul
Timothy B Frigo
Howard Bengele
Jerome M Lewis
Original Assignee
Amag Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22436002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1169062(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amag Pharmaceuticals Inc filed Critical Amag Pharmaceuticals Inc
Publication of PT1169062E publication Critical patent/PT1169062E/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Ceramic Engineering (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compounds Of Iron (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
  • Cookers (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Materials Applied To Surfaces To Minimize Adherence Of Mist Or Water (AREA)
PT00914867T 1999-04-09 2000-03-08 Óxidos de ferro coloidais termoestáveis revestidos PT1169062E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12857999P 1999-04-09 1999-04-09

Publications (1)

Publication Number Publication Date
PT1169062E true PT1169062E (pt) 2009-12-17

Family

ID=22436002

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00914867T PT1169062E (pt) 1999-04-09 2000-03-08 Óxidos de ferro coloidais termoestáveis revestidos

Country Status (11)

Country Link
US (2) US6599498B1 (enExample)
EP (1) EP1169062B1 (enExample)
JP (2) JP5064612B2 (enExample)
AT (1) ATE446108T1 (enExample)
CY (1) CY1109527T1 (enExample)
DE (1) DE60043188D1 (enExample)
DK (1) DK1169062T3 (enExample)
ES (1) ES2334555T3 (enExample)
LU (1) LU92114I2 (enExample)
PT (1) PT1169062E (enExample)
WO (1) WO2000061191A2 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
US7169618B2 (en) * 2000-06-28 2007-01-30 Skold Technology Magnetic particles and methods of producing coated magnetic particles
US6690962B2 (en) 2000-09-15 2004-02-10 Institut fur Diagnostikforshung GmbH Process for graphic visualization and diagnosis of thrombi by means of nuclear spin tomography with use of particulate contrast media
DE10046514A1 (de) * 2000-09-15 2002-04-25 Diagnostikforschung Inst Verfahren zur bildlichen Darstellung und Diagnose von Thromben mittels Kernspintomographie unter Verwendung partikulärer Kontrastmittel
AU2002220280A1 (en) * 2000-12-07 2002-06-18 Ad "Zdravlje" Farmaceutsko - Hemijska Industrija, Centar Za Istrazivanje I Razvoj Polynuclear complex fe(iii) with pullulan oligomers, process of its obtaining, and pharmaceutical preparations on the basis of the complex
WO2003002159A1 (en) * 2001-06-29 2003-01-09 Biovitrum Ab Process for bulk autoclaving
EP1469989B1 (en) 2002-01-02 2011-12-14 Visen Medical, Inc. Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
US20060018835A1 (en) * 2004-04-02 2006-01-26 General Electric Company Nanoparticles with inorganic core and methods of using them
US20060014938A1 (en) * 2004-07-14 2006-01-19 Groman Ernest V Stable aqueous colloidal lanthanide oxides
US20060140867A1 (en) * 2004-12-28 2006-06-29 Helfer Jeffrey L Coated stent assembly and coating materials
CA2606924C (en) 2005-05-09 2013-04-16 The General Hospital Corporation Water relaxation-based sensors
US7564245B2 (en) 2005-08-31 2009-07-21 T2 Biosystems, Inc. NMR device for detection of analytes
US20070077313A1 (en) * 2005-10-04 2007-04-05 U.S. Pharmaceutical Corporation Toleration iron supplement compositions
US9913917B2 (en) 2005-12-22 2018-03-13 Visen Medical, Inc. Biocompatible fluorescent metal oxide nanoparticles
AU2013206429B2 (en) * 2006-01-06 2016-04-28 Vifor (International) Ag Methods and compositions for administration of iron
AU2016205002C1 (en) * 2006-01-06 2020-09-24 Vifor (International) Ag Methods and compositions for administration of iron
KR101905340B1 (ko) 2006-01-06 2018-10-05 루이트폴드 파머수티컬스, 인코퍼레이티드 철을 투여하기 위한 방법 및 조성물
NO329127B1 (no) * 2006-09-12 2010-08-30 Epitarget As Sporbart partikulaert materiale for legemiddelavlevering omfattende et matriseeller membranmateriale, et legemiddel, og et T1- og et T2*- magnetisk resonanskontrastmiddel
WO2008057578A1 (en) * 2006-11-08 2008-05-15 T2 Biosystems, Inc. Nmr systems for in vivo detection of analytes
JP5313906B2 (ja) * 2007-04-12 2013-10-09 インダストリー−アカデミック コーペレイション ファウンデイション， ヨンセイ ユニバーシティ 亜鉛が含有された金属酸化物磁性ナノ粒子を含む磁気共鳴映像剤
US20120003160A1 (en) * 2007-06-29 2012-01-05 Amag Pharmaceuticals, Inc. Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session
JP2010540929A (ja) 2007-09-28 2010-12-24 ティツー・バイオシステムズ・インコーポレーテッド プラスチック製サンプル容器を用いるｎｍｒ装置による診断
WO2009061481A1 (en) * 2007-11-06 2009-05-14 T2 Biosystems, Inc. Small magnet and rf coil for magnetic resonance relaxometry
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
CN102067250B (zh) * 2008-04-16 2014-08-27 干细胞技术公司 磁性粒子
WO2010051362A1 (en) 2008-10-29 2010-05-06 T2 Biosystems, Inc. Nmr detection of coagulation time
WO2010091183A2 (en) * 2009-02-04 2010-08-12 The Regents Of The University Of Colorado, A Body Corporate Non-invasive detection of complement-mediated inflammation using cr2-targeted nanoparticles
WO2010110931A2 (en) 2009-03-23 2010-09-30 The Brigham And Women's Hospital, Inc. Glycoconjugate vaccines
JP5426010B2 (ja) 2009-03-25 2014-02-26 ファーマコスモス ホールディング エー／エス 安定な鉄オリゴ糖化合物
US9149024B2 (en) 2009-06-22 2015-10-06 Massachusetts Eye & Ear Infirmary Islet1 (Isl1) and hearing loss
CN106265593B (zh) 2010-05-26 2019-08-13 通用医疗公司 磁性纳米微粒
WO2011153331A2 (en) 2010-06-02 2011-12-08 The General Hospital Corporation Optical sensor conjugates for detecting reactive oxygen and/or reactive nitrogen species in vivo
CN102451185A (zh) 2010-10-19 2012-05-16 长春纳米生技公司 金属离子纳米簇组合物
CN103384724B (zh) 2010-10-22 2017-11-17 T2生物系统公司 用于检测分析物的核磁共振系统和方法
US8563298B2 (en) 2010-10-22 2013-10-22 T2 Biosystems, Inc. NMR systems and methods for the rapid detection of analytes
US8409807B2 (en) 2010-10-22 2013-04-02 T2 Biosystems, Inc. NMR systems and methods for the rapid detection of analytes
CN102086232B (zh) * 2010-12-15 2012-05-23 吕辉 一种多糖铁的制备方法
US9599627B2 (en) 2011-07-13 2017-03-21 T2 Biosystems, Inc. NMR methods for monitoring blood clot formation
BR112014002986A2 (pt) 2011-08-10 2017-06-13 Adocia composição sob a forma de uma solução injetável, e formulação de dose única
EP2748651B1 (en) 2011-09-21 2017-08-30 T2 Biosystems, Inc. Nmr methods for endotoxin analysis
US9958416B2 (en) 2011-11-23 2018-05-01 The General Hospital Corporation Analyte detection using magnetic hall effect
CN107583039A (zh) 2012-01-09 2018-01-16 阿道恰公司 Ph为7且至少含pi为5.8至8.5之基础胰岛素和取代共聚(氨基酸)的可注射溶液
EP2647389A1 (en) 2012-04-04 2013-10-09 Charité - Universitätsmedizin Berlin Magnetic nanoparticle dispersion, its preparation and diagnostic and therapeutic use
WO2013158281A1 (en) 2012-04-20 2013-10-24 T2 Biosystems, Inc. Compositions and methods for detection of candida species
WO2013187954A1 (en) 2012-06-12 2013-12-19 The General Hospital Corporation Magnetic labeling of bacteria
US9278353B2 (en) 2012-06-25 2016-03-08 The General Hospital Corporation Sorting particles using high gradient magnetic fields
US9675640B2 (en) * 2012-08-07 2017-06-13 Southwest Research Institute Magnetic calcium phosphate nanoparticles, applications and methods of preparation thereof
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
US9739733B2 (en) 2012-12-07 2017-08-22 T2 Biosystems, Inc. Methods for monitoring tight clot formation
US9657098B2 (en) 2013-03-15 2017-05-23 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
US9370202B2 (en) 2013-03-15 2016-06-21 LG Bionano, LLC Encapsulated metal ion nanoclusters
WO2015058206A1 (en) 2013-10-18 2015-04-23 The General Hosptial Corporation Microfluidic sorting using high gradient magnetic fields
US9566216B2 (en) 2013-11-18 2017-02-14 Southwest Research Institute Bone cements containing magnetic calcium phosphate nanoparticles
KR20150078375A (ko) 2013-12-30 2015-07-08 한화케미칼 주식회사 철산화물 나노입자를 포함하는 철결핍증의 예방 또는 치료용 약학 조성물
WO2015108783A1 (en) 2014-01-16 2015-07-23 The Brigham And Women's Hospital, Inc. Targeted delivery of immunoregulatory drugs
TWI689310B (zh) 2014-07-11 2020-04-01 巨生生醫股份有限公司 治療鐵缺乏症之方法
EP3197915A4 (en) 2014-09-22 2018-12-19 Intrinsic Lifesciences LLC Humanized anti-hepcidin antibodies and uses thereof
JP6649377B2 (ja) 2014-11-03 2020-02-19 ザ ジェネラル ホスピタル コーポレイション ミクロ流体装置による粒子の複合式分類および濃縮
CN105597105B (zh) * 2014-11-19 2020-03-10 连云港润众制药有限公司 一种菲立莫妥的制备方法
WO2016154362A1 (en) 2015-03-23 2016-09-29 The Brigham And Women's Hospital, Inc. Tolerogenic nanoparticles for treating diabetes mellitus
US10258647B2 (en) 2015-09-01 2019-04-16 Particle Dynamics International, Llc Iron-polysaccharide complexes and methods for the preparation thereof
US11519016B2 (en) 2016-01-21 2022-12-06 T2 Biosystems, Inc. NMR methods and systems for the rapid detection of bacteria
CN105708805A (zh) * 2016-01-28 2016-06-29 山西普德药业股份有限公司 一种还原型羧烷基葡聚糖铁及其制备方法
CN105708792A (zh) * 2016-01-28 2016-06-29 山西普德药业股份有限公司 一种还原型羧烷基葡聚糖铁注射液及其制备方法
CN105616372A (zh) * 2016-01-28 2016-06-01 山西普德药业股份有限公司 一种还原型羧烷基葡聚糖铁片剂
TR201703251A2 (tr) 2017-03-03 2017-07-21 Berna Buelbuel Kansizliğin transdermal yoldan tedavi̇si̇nde kullanilacak demi̇r oksi̇t nanokri̇stalleri̇ i̇çeren solüsyon
CN108403716B (zh) * 2018-06-25 2021-11-05 博瑞生物医药（苏州）股份有限公司 一种超顺磁氧化铁的制备方法
CA3130103A1 (en) 2019-02-13 2020-08-20 The Brigham And Women's Hospital, Inc. Anti-peripheral lymph node addressin antibodies and uses thereof
WO2025043086A1 (en) 2023-08-22 2025-02-27 Navinta, Llc An improved process for the preparation of solid ferumoxytol

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2885393A (en) 1956-02-24 1959-05-05 R K Laros Company Dextran-iron complex and process for making same
US2862920A (en) 1956-06-07 1958-12-02 Ohio Commw Eng Co Ferrous carboxymethyl dextran
US3000872A (en) 1956-06-15 1961-09-19 Ohio Commw Eng Co Preparation of carboxymethyl dextran-iron complexes
US2856398A (en) 1956-06-15 1958-10-14 Ohio Commw Eng Co Carboxymethyl dextran-iron complexes
US2856366A (en) 1956-07-30 1958-10-14 Ohio Commw Eng Co Stable alkaline metal solutions containing carboxymethyl dextran
US3151107A (en) 1960-12-22 1964-09-29 Central Pharmacal Company Water-soluble iron complexes of carboxymethyl dextran
GB1019513A (en) * 1961-08-07 1966-02-09 Chemicals Inc Iron dextran complexes
US3234209A (en) * 1963-09-13 1966-02-08 Chemicals Inc Process for making iron hydrogenated dextran
JPS5913521B2 (ja) 1975-06-19 1984-03-30 メイトウサンギヨウ カブシキガイシヤ 磁性酸化鉄・デキストラン複合体の製造法
US4180567A (en) 1977-09-02 1979-12-25 Pharmachem Corporation Iron preparations and methods of making and administering the same
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US5076950A (en) 1985-12-20 1991-12-31 Syntex (U.S.A.) Inc. Magnetic composition for particle separation
DE3684448D1 (de) 1985-12-20 1992-04-23 Syntex Inc Teilchentrennungsverfahren.
US4827945A (en) * 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US5102652A (en) 1986-07-03 1992-04-07 Advanced Magnetics Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
US5262176A (en) 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
US4770183A (en) 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US5055288A (en) 1987-06-26 1991-10-08 Advanced Magnetics, Inc. Vascular magnetic imaging method and agent comprising biodegradeable superparamagnetic metal oxides
US5160726A (en) 1990-02-15 1992-11-03 Advanced Magnetics Inc. Filter sterilization for production of colloidal, superparamagnetic MR contrast agents
GB8808305D0 (en) * 1988-04-08 1988-05-11 Nycomed As Compositions
JP2726520B2 (ja) * 1989-10-20 1998-03-11 名糖産業株式会社 有機磁性複合体
EP0506880A1 (en) 1989-12-22 1992-10-07 Molecular Bioquest, Inc. Organo-metallic coated particles for use in separations
GB9416767D0 (en) * 1994-08-18 1994-10-12 Nycomed Innovation Ab Compositions
AU687093B2 (en) 1994-09-27 1998-02-19 Nycomed Imaging As Contrast agent
AU4031797A (en) 1996-08-30 1998-03-19 Meito Sangyo Kabushiki Kaisha Polysaccharide derivative/magnetic metal oxide composite
DK172860B1 (da) * 1998-03-25 1999-08-16 Pharmacosmos Holding As Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
DK173138B1 (da) * 1998-11-20 2000-02-07 Pharmacosmos Holding As Fremgangsmåde til fremstilling af en jerndextranforbindelse, jerndextranforbindelse fremstillet efter fremgangsmåden, farma

Also Published As

Publication number Publication date
DE60043188D1 (de) 2009-12-03
EP1169062A2 (en) 2002-01-09
CY1109527T1 (el) 2014-08-13
JP5064612B2 (ja) 2012-10-31
WO2000061191A9 (en) 2001-06-21
WO2000061191A2 (en) 2000-10-19
US20030225033A1 (en) 2003-12-04
ATE446108T1 (de) 2009-11-15
EP1169062B1 (en) 2009-10-21
ES2334555T3 (es) 2010-03-12
JP2002541218A (ja) 2002-12-03
DK1169062T3 (da) 2010-01-25
LU92114I2 (fr) 2013-12-14
US7553479B2 (en) 2009-06-30
JP2011046752A (ja) 2011-03-10
US6599498B1 (en) 2003-07-29
WO2000061191A3 (en) 2001-05-25

Similar Documents

Publication Publication Date Title
PT1169062E (pt) Óxidos de ferro coloidais termoestáveis revestidos
AU2002355333A1 (en) Conjugates of macrocyclic metal complexes with biomolecules and the utilization thereof for producing agents for use in NMR diagnosis and radiodiagnosis and radiotherapy
IL159291A0 (en) Conjugates of macrocyclic metal complexes with biomolecules and the utilization thereof for producing agents for use in nmr diagnosis and radiodiagnosis and radiotherapy
AU1073601A (en) Fullerene contrast agent for magnetic resonance imaging and spectroscopy
AU5540400A (en) Bicyclic polyaminoacid metal complexes, method for preparing same and use in medical imaging
PL356908A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU1240801A (en) Coil structures and methods for generating magnetic fields
AU1945901A (en) Hydroxylamine seeding of colloidal metal nanoparticles
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
IL116209A0 (en) Metal complexes and complexing agents as x-ray contrast media
AU4064401A (en) Bile acids conjugates with metal ion chelates and the use thereof
AU2489300A (en) Contrast agent enhanced magnetic resonance angiography with vessel segmentation
AU2921095A (en) Iron-containing nanoparticles with double coating and their use in diagnosis and therapy
AU2001275476A1 (en) An implantable medical device with aregarding coil magnetic shield
AU2003253688A1 (en) Magnetically shielded room with internal active magnetic field cancellation, and its use
WO2002013874A8 (de) Verwendung von perfluoralkylhaltigen metallkomplexen als kontrastmittel im mr-imaging zur darstellung von plaques, tumoren und nekrosen
AU2001277549A1 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses
AU2001255241A1 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
EP0778563A3 (en) Magnetoresistive device incorporating conductor geometry providing substantially uniform current flow for improved magnetic stability
AU3221195A (en) Macrocyclic chelants, their chelates and uses thereof in the diagnostic field
AU6540400A (en) Active hybrid with dynamic impedance matching against different loop conditions and related method
Parker Targeting metal complexes
AU2001292797A1 (en) Metal complexes for use in medical and therapeutic applications
AU5851600A (en) Carbon powder having enhanced electrical characteristics and use of the same
AU2001230571A1 (en) Ultrafine mixed-crystal oxide particles, process for producing the same, and use